Furthermore, several studies have explored the combination of afatinib and cetuximab as a potential treatment option for NSCLC with EGFR exon 20 insertion mutations, suggesting that cetuximab may be able to increase the efficacy of afatinib in NSCLC with EGFR exon 20 insertion mutations [39,40]. Here, EGFR is linked to non-small cell lung carcinoma.